Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
Active, not recruiting · NCT04588545 · Registry updated 2026-05-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease | Neoplasms by Site, central nervous system cancer, neoplasm, neoplastic meningitis, nervous system disorder, tumor of meninges | Active, not recruiting | Phase 1 / Phase 2 | 2026-05-26 | NCT04588545 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Genentech, Inc. | 221 |
| H. Lee Moffitt Cancer Center and Research Institute | 162 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Moffitt Cancer Center | Tampa | United States | 523 |
| Northwestern University | Evanston | United States | 53 |